Melkart

Vildagliptin, the active ingredient in Melkart, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when combined with diet and exercise.

GNH USA supplies Melkart as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides reliable global distribution, and manufactures products under GMP conditions for bulk procurement.

Vildagliptin is used in the treatment of type 2 diabetes mellitus, targeting the incretin pathway to improve glucose regulation. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as a single agent. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin or other oral antidiabetics. - Type 2 diabetes mellitus (adjunct to insulin): reduces insulin requirements and helps achieve target HbA1c.

Vildagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Headache: transient tension‑type headache. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: symptoms of common cold. - Nasopharyngitis: irritation of the nasal passages. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction. - Severe hypoglycaemia: prolonged low blood glucose, especially with other hypoglycaemic agents.

When prescribing Vildagliptin, clinicians should consider several safety aspects to minimise risk. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly. - Elderly patients: watch for hypoglycaemia, especially with concomitant sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Drug interactions: review all concomitant medications for possible additive hypoglycaemic effect. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Vildagliptin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Insulin: may cause severe hypoglycaemia. - Sulfonylureas (e.g., glimepiride): increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce plasma concentrations of Vildagliptin. - Diuretics: may affect glucose homeostasis. - ACE inhibitors: monitor renal function and potassium levels.